Literature DB >> 16690782

Mechanisms of cardiolipin oxidation by cytochrome c: relevance to pro- and antiapoptotic functions of etoposide.

Yulia Y Tyurina1, Vidisha Kini, Vladimir A Tyurin, Irina I Vlasova, Jianfei Jiang, Alexander A Kapralov, Natalia A Belikova, Jack C Yalowich, Igor V Kurnikov, Valerian E Kagan.   

Abstract

Execution of apoptotic program in mitochondria is associated with accumulation of cardiolipin peroxidation products required for the release of proapoptotic factors into the cytosol. This suggests that lipid antioxidants capable of inhibiting cardiolipin peroxidation may act as antiapoptotic agents. Etoposide, a widely used antitumor drug and a topoisomerase II inhibitor, is a prototypical inducer of apoptosis and, at the same time, an effective lipid radical scavenger and lipid antioxidant. Here, we demonstrate that cardiolipin oxidation during apoptosis is realized not via a random cardiolipin peroxidation mechanism but rather proceeds as a result of peroxidase reaction in a tight cytochrome c/cardiolipin complex that restrains interactions of etoposide with radical intermediates generated in the course of the reaction. Using low-temperature and ambient-temperature electron paramagnetic resonance spectroscopy of H(2)O(2)-induced protein-derived (tyrosyl) radicals and etoposide phenoxyl radicals, respectively, we established that cardiolipin peroxidation and etoposide oxidation by cytochrome c/cardiolipin complex takes place predominantly on protein-derived radicals of cytochrome c. We further show that etoposide can inhibit cytochrome c-catalyzed oxidation of cardiolipin competing with it as a peroxidase substrate. Peroxidase reaction of cytochrome c/cardiolipin complexes causes cross-linking and oligomerization of cytochrome c. With nonoxidizable tetraoleoyl-cardiolipin, the cross-linking occurs via dityrosine formation, whereas bifunctional lipid oxidation products generated from tetralinoleoyl-cardiolipin participate in the production of high molecular weight protein aggregates. Protein aggregation is effectively inhibited by etoposide. The inhibition of cardiolipin peroxidation by etoposide, however, is realized at far higher concentrations than those at which it induces apoptotic cell death. Thus, oxidation of cardiolipin by the cytochrome c/cardiolipin peroxidase complex, which is essential for apoptosis, is not inhibited by proapoptotic concentrations of the drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690782     DOI: 10.1124/mol.106.022731

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  32 in total

1.  Cardiolipin Interactions with Proteins.

Authors:  Joan Planas-Iglesias; Himal Dwarakanath; Dariush Mohammadyani; Naveena Yanamala; Valerian E Kagan; Judith Klein-Seetharaman
Journal:  Biophys J       Date:  2015-08-20       Impact factor: 4.033

Review 2.  Therapies targeting lipid peroxidation in traumatic brain injury.

Authors:  Tamil Selvan Anthonymuthu; Elizabeth Megan Kenny; Hülya Bayır
Journal:  Brain Res       Date:  2016-02-10       Impact factor: 3.252

3.  Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells.

Authors:  Irina I Vlasova; Wei-Hong Feng; Julie P Goff; Angela Giorgianni; Duc Do; Susanne M Gollin; Dale W Lewis; Valerian E Kagan; Jack C Yalowich
Journal:  Mol Pharmacol       Date:  2010-11-19       Impact factor: 4.436

4.  Molecular design of new inhibitors of peroxidase activity of cytochrome c/cardiolipin complexes: fluorescent oxadiazole-derivatized cardiolipin.

Authors:  G G Borisenko; A A Kapralov; V A Tyurin; A Maeda; D A Stoyanovsky; V E Kagan
Journal:  Biochemistry       Date:  2008-12-23       Impact factor: 3.162

5.  Peroxidase activity of hemoglobin-haptoglobin complexes: covalent aggregation and oxidative stress in plasma and macrophages.

Authors:  Alexandr Kapralov; Irina I Vlasova; Weihong Feng; Akihiro Maeda; Karen Walson; Vladimir A Tyurin; Zhentai Huang; Rajesh K Aneja; Joseph Carcillo; Hülya Bayir; Valerian E Kagan
Journal:  J Biol Chem       Date:  2009-09-08       Impact factor: 5.157

6.  Peroxidase activation of cytoglobin by anionic phospholipids: Mechanisms and consequences.

Authors:  Jesús Tejero; Alexandr A Kapralov; Matthew P Baumgartner; Courtney E Sparacino-Watkins; Tamil S Anthonymutu; Irina I Vlasova; Carlos J Camacho; Mark T Gladwin; Hülya Bayir; Valerian E Kagan
Journal:  Biochim Biophys Acta       Date:  2016-02-27

Review 7.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

Review 8.  Cytochrome c/cardiolipin relations in mitochondria: a kiss of death.

Authors:  Valerian E Kagan; Hülya A Bayir; Natalia A Belikova; Olexandr Kapralov; Yulia Y Tyurina; Vladimir A Tyurin; Jianfei Jiang; Detcho A Stoyanovsky; Peter Wipf; Patrick M Kochanek; Joel S Greenberger; Bruce Pitt; Anna A Shvedova; Grigory Borisenko
Journal:  Free Radic Biol Med       Date:  2009-03-12       Impact factor: 7.376

9.  Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease.

Authors:  Hülya Bayir; Alexandr A Kapralov; Janfei Jiang; Zhentai Huang; Yulia Y Tyurina; Vladimir A Tyurin; Qing Zhao; Natalia A Belikova; Irina I Vlasova; Akihiro Maeda; Jianhui Zhu; Hye-Mee Na; Pier-Giorgio Mastroberardino; Louis J Sparvero; Andrew A Amoscato; Charleen T Chu; John T Greenamyre; Valerian E Kagan
Journal:  J Biol Chem       Date:  2009-04-07       Impact factor: 5.157

10.  Recombinant expression, biophysical characterization, and cardiolipin-induced changes of two Caenorhabditis elegans cytochrome c proteins.

Authors:  Amber J Vincelli; Danielle S Pottinger; Fangfang Zhong; Jonas Hanske; Stéphane G Rolland; Barbara Conradt; Ekaterina V Pletneva
Journal:  Biochemistry       Date:  2013-01-16       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.